Sage Journals: Discover world-class research

Open access

Research article

First published 2020

CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis

Jeroen FJ Bogie, Elien Grajchen, Elien Wouters [...]

Sage Open Chronic Disease

Free access

Research article

First published 2007-4

A New Sensitive Enzyme-Linked Immunosorbent Assay (ELISA) for Alemtuzumab Determination: Development,Validation and Application

M. Montagna, M.A. Avanzini, L. Visai [...]

International Journal of Immunopathology and Pharmacology

Retricted access

Research article

First published 2018-08

Alemtuzumab,a Monoclonal Antibody to CD52,Frequently Causes Graves’ Disease

Jerome M. Hershman

Clinical Thyroidology®

Open access

Review article

First published 2015-1

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis

Hans-Peter Hartung, Orhan Aktas, Alexey N Boyko

Multiple Sclerosis Journal

Free access

Review article

First published 2012-12

Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use

Jeremy L. Warner, Jon E. Arnason

Therapeutic Advances in Hematology

Retricted access

Research article

First published 2020-06

Bioinformatics Analysis of Microarray Datasets to Identify Prognostic Factors in Lung Adenocarcinoma

Xiang Jin, Lijun Xu, Yinghui Guan [...]

DNA and Cell Biology

Open access

Research article

First published 2021

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Alasdair J. Coles, Douglas L. Arnold, Ann D. Bass [...]

Therapeutic Advances in Neurological Disorders

Retricted access

Case report

First published 2017-5

Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab

Marinella Clerico, Stefania De Mercanti, Carlo Alberto Artusi [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2017-9

Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis

Rafael Arroyo González, Mariko Kita, Heidi Crayton [...]

Multiple Sclerosis Journal

Free access

Review article

First published 2013-5

Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects

Onajite Kousin-Ezewu, Alasdair Coles

Sage Open Chronic Disease

Search results